Top 10 Drug Delivery Technologies Market

Report Description

STUDY GOALS AND OBJECTIVES

  • To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.
  • To identify major drivers and restraints of the market
  • To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.
  • To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.
  • To analyze trends and forecasts of drug delivery market and its segments
  • To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
  • To analyze opportunities in the market for stakeholders
  • To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
  • To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
  • To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
  • To provide comprehensive analysis of top players in the drug delivery technology market.
  • To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.

REASONS FOR DOING THE STUDY

More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.

SCOPE AND FORMAT

The report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:

  • Oral drug delivery technologies
  • Injectable drug delivery technologies
  • Pulmonary drug delivery technologies
  • Transdermal drug delivery technologies
  • Other drug delivery technologies

The report also focuses on the emerging drug delivery technologies and mechanisms.

INTENDED AUDIENCES

  • Drug delivery technology - manufacturers, suppliers and dealers
  • Pharmaceutical and biotech companies
  • Healthcare providers
  • Potential investors in the drug delivery technology market

INFORMATION SOURCES

Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.

  • EXECUTIVE SUMMARY
    • OBJECTIVE
    • MARKET SCENARIO
    • EMERGING TECHNOLOGIES
  • 1 INTRODUCTION
    • 1.1 KEY TAKE-AWAYS
    • 1.2 REPORT DESCRIPTION
    • 1.3 MARKETS COVERED
    • 1.4 STAKEHOLDERS
    • 1.5 RESEARCH METHODOLOGY
  • 2 SUMMARY
  • 3 MARKET OVERVIEW
    • 3.1 INTRODUCTION
    • 3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
    • 3.3 STAKEHOLDERS
    • 3.4 CHALLENGES
      • 3.4.1 GOVERNMENT REGULATIONS
      • 3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE
      • 3.4.3 PATENT LITIGATIONS
      • 3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
    • 3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
    • 3.6 PATENT ANALYSIS
  • 4 MARKET DYNAMICS
    • 4.1 INTRODUCTION
    • 4.2 DRIVERS
      • 4.2.1 PATENT EXPIRATION OF DRUGS
      • 4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS
      • 4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES
      • 4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
      • 4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
    • 4.3 RESTRAINTS
      • 4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI
      • 4.3.2 U.S. HEALTHCARE REFORMS
    • 4.4 OPPORTUNITIES
      • 4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION
      • 4.4.2 NICHE THERAPEUTIC AREAS
      • 4.4.3 WELLNESS PRODUCTS
  • 5 CONTROLLED RELEASE TECHNOLOGY
    • 5.1 INTRODUCTION
      • 5.1.1 KEY MARKET PLAYERS
    • 5.2 DRIVERS
      • 5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
      • 5.2.2 ONCE-A-DAY FORMULATIONS
      • 5.2.3 COST EFFECTIVE
    • 5.3 RESTRAINTS
      • 5.3.1 LIMITED NUMBER OF MATERIALS
      • 5.3.2 TECHNICAL BARRIERS
    • 5.4 OPPORTUNITIES
      • 5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS
      • 5.4.2 MUCOADHESIVE DRUG DELIVERY
    • 5.5 BIODEGRADABLE POLYMERS
    • 5.6 HYDROGEL
    • 5.7 MULTIPARTICULATE BEAD SYSTEMS
    • 5.8 ION EXCHANGE RESINS
    • 5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS
    • 5.10 DISSOLUTION/DIFFUSION SYSTEMS
      • 5.10.1 MATRIX SYSTEMS
      • 5.10.2 RESERVOIR SYSTEMS
    • 5.11 OTHERS
    • 5.12 REGULATORY ENVIRONMENT
    • 5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
    • 5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES
    • 5.15 BURNING ISSUES
    • 5.16 WINNING IMPERATIVES
    • 5.17 COMPETITIVE DEVELOPMENTS
  • 6 TARGETED DELIVERY
    • 6.1 INTRODUCTION
      • 6.1.1 KEY MARKET PLAYERS
    • 6.2 DRIVERS & RESTRAINTS
      • 6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
      • 6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
      • 6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
    • 6.3 OPPORTUNITY
      • 6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
    • 6.4 TARGETING LIGANDS
      • 6.4.1.1 Antibody fragment drug conjugate delivery
      • 6.4.1.2 Antibody directed enzyme prodrug targeted delivery
      • 6.4.1.3 Peptide-targeted delivery
      • 6.4.1.4 Small molecule conjugate delivery
      • 6.4.1.5 Others
    • 6.5 NON-BIOLOGICAL TARGETING PLATFORMS
    • 6.6 CURRENTLY MARKETED TARGETED THERAPIES
    • 6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS
    • 6.8 INNOVATIONS
    • 6.9 INDUSTRY INSIGHTS
    • 6.10 WINNING IMPERATIVES
  • 7 ENCAPSULATION TECHNOLOGIES
    • 7.1 INTRODUCTION
      • 7.1.1 KEY MARKET PLAYERS
    • 7.2 DRIVERS & RESTRAINTS
      • 7.2.1 ENHANCED BIOAVAILABILITY
      • 7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS
      • 7.2.3 ECONOMICALLY FEASIBLE
      • 7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
    • 7.3 OPPORTUNITY
      • 7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
    • 7.4 TASTE MASKING
    • 7.5 FAST DISSOLVING PILLS
    • 7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
    • 7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
    • 7.8 INDUSTRY INSIGHTS
    • 7.9 WINNING IMPERATIVES
    • 7.10 COMPETITIVE DEVELOPMENTS
  • 8 TOPICAL FORMULATIONS
    • 8.1 INTRODUCTION
      • 8.1.1 KEY MARKET PLAYERS
    • 8.2 DRIVERS & RESTRAINTS
      • 8.2.1 BURN & WOUND TREATMENT
      • 8.2.2 BYPASSING FIRST PASS EFFECT
      • 8.2.3 CONVENIENCE FACTOR
      • 8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS
    • 8.3 OPPORTUNITY
      • 8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
    • 8.4 GEL TECHNOLOGY
    • 8.5 MICROEMULSIONS
    • 8.6 BIPHASIC SYSTEM
    • 8.7 OTHERS
    • 8.8 INDUSTRY INSIGHTS
    • 8.9 WINNING IMPERATIVES
    • 8.10 COMPETITIVE DEVELOPMENTS
  • 9 INHALER TECHNOLOGY
    • 9.1 INTRODUCTION
      • 9.1.1 KEY MARKET PLAYERS
    • 9.2 DRIVERS & RESTRAINTS
      • 9.2.1 INCREASE IN ASTHMA & COPD PATIENTS
      • 9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
      • 9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY
      • 9.2.4 FAILURE OF EXUBERA
    • 9.3 OPPORTUNITY
      • 9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
    • 9.4 DRY POWDER INHALERS
    • 9.5 METERED DOSE INHALERS
    • 9.6 NEBULIZERS
    • 9.7 EVOLUTION OF INHALER DEVICES
    • 9.8 REGULATORY ENVIRONMENT
    • 9.9 TECHNOLOGY INNOVATIONS
    • 9.10 INDUSTRY INSIGHTS
    • 9.11 WINNING IMPERATIVES
    • 9.12 COMPETITIVE DEVELOPMENTS
  • 10 INJECTABLE DRUG DELIVERY
    • 10.1 INJECTION DEVICES
      • 10.1.1 KEY MARKET DYNAMICS
        • 10.1.1.1 Drivers
        • 10.1.1.1.1 Growth of self-administration therapies
        • 10.1.1.1.2 Needle-stick legislation
        • 10.1.1.1.3 Increasing acceptance by physicians and patients
        • 10.1.1.1.4 Reducing cost of treatment
        • 10.1.1.2 Restraints
        • 10.1.1.2.1 Need of new drug formulation
        • 10.1.1.3 Opportunities
        • 10.1.1.3.1 Product differentiation through added functional features
        • 10.1.1.3.2 Expansion to new areas
    • 10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
    • 10.3 KEY DEVELOPMENTS
      • 10.3.1 DEVELOPMENT OF MICRONEEDLES
      • 10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
    • 10.4 CONVENTIONAL INJECTABLES
    • 10.5 PREFILLED SYRINGES (PFS)
      • 10.5.1 KEY MARKET DYNAMICS
        • 10.5.1.1 Drivers
        • 10.5.1.1.1 Growing market for self-injection devices
        • 10.5.1.1.2 Wastage control and cost reduction through less overfill
        • 10.5.1.1.3 Ease of manufacture & convenient usability
        • 10.5.1.2 Restraints
        • 10.5.1.2.1 Threat from needle-free devices
        • 10.5.1.2.2 Protecting product quality
      • 10.5.2 GLASS PFS
      • 10.5.3 PLASTIC PFS
    • 10.6 SELF INJECTION DEVICES
      • 10.6.1 AUTO INJECTORS
        • 10.6.1.1 Reusable auto-injectors
        • 10.6.1.2 Disposable auto-injectors
      • 10.6.2 PEN INJECTORS
        • 10.6.2.1 Reusable pen injectors
        • 10.6.2.2 Disposable pen injectors
      • 10.6.3 NEEDLE-FREE INJECTORS (NFI)
        • 10.6.3.1 Reusable NFIs
        • 10.6.3.2 Disposable NFIs
    • 10.7 OTHERS
  • 11 TRANSDERMAL PATCH
    • 11.1 INTRODUCTION
      • 11.1.1 KEY MARKET PLAYERS
    • 11.2 DRIVERS
      • 11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
      • 11.2.2 CONVENIENT & LESS PAINFUL
    • 11.3 RESTRAINTS
      • 11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
      • 11.3.2 LOW SKIN PERMEABILITY OF DRUGS
    • 11.4 OPPORTUNITIES
      • 11.4.1 NEW PRODUCTS
        • 11.4.1.1 Contraceptive patch
        • 11.4.1.2 Pain management patch
        • 11.4.1.3 Estrogen/hormone replacement patch
    • 11.5 INDUSTRY INSIGHTS
    • 11.6 WINNING IMPERATIVES
    • 11.7 COMPETITIVE DEVELOPMENTS
  • 12 IMPLANTABLE DRUG DELIVERY
    • 12.1 INTRODUCTION
    • 12.2 DRIVERS & RESTRAINTS
      • 12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT
      • 12.2.2 DOSING ADMINISTRATION NOT REQUIRED
      • 12.2.3 INCONVENIENCE
    • 12.3 OPPORTUNITY
      • 12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
    • 12.4 CORONARY (DRUG ELUTING) STENTS
    • 12.5 IMPLANTABLE INFUSION PUMPS
    • 12.6 OCULAR IMPLANTS & OTHERS
    • 12.7 INDUSTRY INSIGHTS
    • 12.8 WINNING IMPERATIVES
  • 13 LIPOSOMAL DRUG DELIVERY
    • 13.1 INTRODUCTION
    • 13.2 DRIVERS & RESTRAINTS
      • 13.2.1 ENHANCED USAGE IN CANCER
      • 13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS
      • 13.2.3 SIDE EFFECTS
    • 13.3 OPPORTUNITY
      • 13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY
    • 13.4 INDUSTRY INSIGHTS
    • 13.5 WINNING IMPERATIVES
    • 13.6 COMPETITIVE DEVELOPMENTS
  • 14 PEGYLATION TECHNOLOGIES
    • 14.1 INTRODUCTION
    • 14.2 DRIVERS & RESTRAINTS
      • 14.2.1 BIOLOGICAL DRUGS
      • 14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE
      • 14.2.3 EXPENSIVE MANUFACTURING PROCEDURE
    • 14.3 OPPORTUNITY
      • 14.3.1 TECHNOLOGICAL ADVANCES
    • 14.4 INDUSTRY INSIGHTS
    • 14.5 WINNING IMPERATIVES
  • 15 COMPETITIVE LANDSCAPE
    • 15.1 INTRODUCTION
    • 15.2 ANALYSIS OF TOP PLAYERS
      • 15.2.1 STRATEGY
      • 15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE
        • 15.2.2.1 Top injectable drug delivery device companies & revenues, by segment
    • 15.3 WINNING IMPERATIVES
      • 15.3.1 ALLIANCES
      • 15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
      • 15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
    • 15.4 STRATEGIC RECOMMENDATIONS
  • 16 GEOGRAPHIC ANALYSIS
    • 16.1 INTRODUCTION
    • 16.2 NORTH AMERICA
    • 16.3 EUROPE
    • 16.4 ASIA
    • 16.5 REST OF THE WORLD (ROW)
    • 16.6 DECISION SUPPORT DATABASE
  • 17 COMPANY PROFILES
    • 17.1 3M COMPANY
      • 17.1.1 OVERVIEW
      • 17.1.2 FINANCIALS
      • 17.1.3 PRODUCTS & SERVICES
      • 17.1.4 STRATEGY
      • 17.1.5 DEVELOPMENTS
    • 17.2 ALKERMES, INC
      • 17.2.1 OVERVIEW
      • 17.2.2 FINANCIALS
      • 17.2.3 PRODUCTS & SERVICES
      • 17.2.4 STRATEGY
      • 17.2.5 DEVELOPMENTS
    • 17.3 ALTEA THERAPEUTICS INC.
      • 17.3.1 OVERVIEW
      • 17.3.2 PRODUCTS & SERVICES
      • 17.3.3 STRATEGY
      • 17.3.4 DEVELOPMENTS
    • 17.4 ANTARES PHARMA INC.
      • 17.4.1 OVERVIEW
      • 17.4.2 FINANCIALS
      • 17.4.3 PRODUCTS & SERVICES
      • 17.4.4 STRATEGY
      • 17.4.5 DEVELOPMENTS
    • 17.5 A.P. PHARMA, INC.
      • 17.5.1 OVERVIEW
      • 17.5.2 FINANCIALS
      • 17.5.3 PRODUCTS & SERVICES
      • 17.5.4 STRATEGY
      • 17.5.5 DEVELOPMENTS
    • 17.6 APPLIED PHARMA
      • 17.6.1 OVERVIEW
      • 17.6.2 PRODUCTS & SERVICES
      • 17.6.3 STRATEGY
      • 17.6.4 DEVELOPMENTS
    • 17.7 ARADIGM CORPORATION
      • 17.7.1 OVERVIEW
      • 17.7.2 FINANCIALS
      • 17.7.3 PRODUCTS & SERVICES
      • 17.7.4 STRATEGY
      • 17.7.5 DEVELOPMENTS
    • 17.8 BAXTER BIOPHARMA
      • 17.8.1 OVERVIEW
      • 17.8.2 PRODUCTS & SERVICES
      • 17.8.3 FINANCIALS
      • 17.8.4 STRATEGY
      • 17.8.5 DEVELOP0MENTS
    • 17.9 BECTON, DICKINSON AND COMPANY
      • 17.9.1 OVERVIEW
      • 17.9.2 PRODUCT & SERVICES
      • 17.9.3 FINANCIALS
      • 17.9.4 STRATEGY
      • 17.9.5 DEVELOPMENTS
    • 17.10 BIOJECT INC.
      • 17.10.1 OVERVIEW
      • 17.10.2 FINANCIALS
      • 17.10.3 PRODUCTS & SERVICES
      • 17.10.4 STRATEGY
      • 17.10.5 DEVELOPMENTS
    • 17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)
      • 17.11.1 OVERVIEW
      • 17.11.2 PRODUCTS & SERVICES
      • 17.11.3 FINANCIALS
      • 17.11.4 STRATEGY
      • 17.11.5 DEVELOPMENTS
    • 17.12 CIMA LABS INC.
      • 17.12.1 OVERVIEW
      • 17.12.2 PRODUCTS & SERVICES
      • 17.12.3 STRATEGY
      • 17.12.4 DEVELOPMENTS
    • 17.13 ELAN CORPORATION PLC.
      • 17.13.1 OVERVIEW
      • 17.13.2 FINANCIALS
      • 17.13.3 PRODUCTS & SERVICES
      • 17.13.4 STRATEGY
      • 17.13.5 DEVELOPMENTS
    • 17.14 ENDO PHARMACEUTICALS
      • 17.14.1 OVERVIEW
      • 17.14.2 FINANCIALS
      • 17.14.3 PRODUCTS & SERVICES
      • 17.14.4 STRATEGY
      • 17.14.5 DEVELOPMENTS
    • 17.15 EURAND PHARMACEUTICALS
      • 17.15.1 OVERVIEW
      • 17.15.2 FINANCIALS
      • 17.15.3 PRODUCTS & SERVICES
      • 17.15.4 STRATEGY
      • 17.15.5 DEVELOPMENTS
    • 17.16 FLAMEL TECHNOLOGIES, INC
      • 17.16.1 OVERVIEW
      • 17.16.2 FINANCIALS
      • 17.16.3 PRODUCTS & SERVICES
      • 17.16.4 STRATEGY
      • 17.16.5 DEVELOPMENTS
    • 17.17 JOHNSON & JOHNSON LTD.
      • 17.17.1 OVERVIEW
      • 17.17.2 FINANCIALS
      • 17.17.3 PRODUCTS & SERVICES
      • 17.17.4 STRATEGY
      • 17.17.5 DEVELOPMENTS
    • 17.18 KV PHARMACEUTICAL
      • 17.18.1 OVERVIEW
      • 17.18.2 FINANCIALS
      • 17.18.3 PRODUCTS & SERVICES
      • 17.18.4 STRATEGY
      • 17.18.5 DEVELOPMENTS
    • 17.19 LABOPHARM INC.
      • 17.19.1 OVERVIEW
      • 17.19.2 FINANCIALS
      • 17.19.3 PRODUCTS & SERVICES
      • 17.19.4 STRATEGY
      • 17.19.5 DEVELOPMENTS
    • 17.20 NANOPASS TECHNOLOGIES LTD.
      • 17.20.1 OVERVIEW
      • 17.20.2 PRODUCTS & SERVICES
      • 17.20.3 STRATEGY
      • 17.20.4 DEVELOPMENTS
    • 17.21 NEKTAR THERAPEUTICS
      • 17.21.1 OVERVIEW
      • 17.21.2 FINANCIALS
      • 17.21.3 PRODUCTS & SERVICES
      • 17.21.4 STRATEGY
      • 17.21.5 DEVELOPMENTS
    • 17.22 QLT INC.
      • 17.22.1 OVERVIEW
      • 17.22.2 FINANCIALS
      • 17.22.3 PRODUCTS & SERVICES
      • 17.22.4 STRATEGY
      • 17.22.5 DEVELOPMENTS
    • 17.23 SKYEPHARMA PLC.
      • 17.23.1 OVERVIEW
      • 17.23.2 FINANCIALS
      • 17.23.3 PRODUCTS & SERVICES
      • 17.23.4 STRATEGY
      • 17.23.5 DEVELOPMENTS
    • 17.24 SURMODICS, INC.
      • 17.24.1 OVERVIEW
      • 17.24.2 PRODUCTS & SERVICES
      • 17.24.3 FINANCIALS
      • 17.24.4 STRATEGY
      • 17.24.5 DEVELOPMENTS
    • 17.25 VECTURA GROUP PLC
      • 17.25.1 OVERVIEW
      • 17.25.2 FINANCIALS
      • 17.25.3 PRODUCTS & SERVICES
      • 17.25.4 STRATEGY
      • 17.25.5 DEVELOPMENTS
    • 17.26 YPSOMED HOLDING AG
      • 17.26.1 OVERVIEW
      • 17.26.2 FINANCIALS
      • 17.26.3 PRODUCTS & SERVICES
      • 17.26.4 STRATEGY
      • 17.26.5 DEVELOPMENTS
    • 17.27 ZOGENIX, INC.
      • 17.27.1 OVERVIEW
      • 17.27.2 PRODUCTS & SERVICES
      • 17.27.3 STRATEGY
      • 17.27.4 DEVELOP0MENTS
  • APPENDIX
    • U.S. PATENTS
    • EUROPE PATENTS
    • JAPAN PATENTS
  • LIST OF TABLES
    • TABLE 1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS, 2008-2015 ($MILLION)
    • TABLE 2 DRUGS SET FOR PATENT EXPIRATION, 2010-2012
    • TABLE 3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008-2015 ($MILLION)
    • TABLE 9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008-2015
    • TABLE 34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
    • TABLE 58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS, 2008-2015 ($MILLION)
    • TABLE 59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS, (2008-2015)
    • TABLE 62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY, 2008-2015 ($MILLION)
    • TABLE 70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
    • TABLE 71 REVENUE ANALYSIS, 2008-2009
    • TABLE 72 ELAN TOTAL REVENUES BY DRUG, 2008-2010
    • TABLE 73 ALKERMES TOTAL REVENUES, BY DRUG, 2008-2010
    • TABLE 74 R&D EXPENDITURE, 2008-2009
    • TABLE 75 ELAN?S PIPELINE DRUGS
    • TABLE 76 BIOVAIL?S PIPELINE DRUGS
    • TABLE 77 ALKERMES?S PIPELINE DRUGS
    • TABLE 78 NEKTAR?S PIPELINE DRUGS
    • TABLE 79 SKYE PHARMA?S PIPELINE DRUGS
    • TABLE 80 TOP COMPANIES & THEIR STRATEGIES
    • TABLE 81 BECTON DICKINSON-TOTAL REVENUES, BY SEGMENT ($MILLION)
    • TABLE 82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
    • TABLE 83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)
    • TABLE 84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION, 2008-2015
    • TABLE 85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
    • TABLE 86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
    • TABLE 87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
    • TABLE 88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
    • TABLE 89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 91 DIABETES PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 92 CANCER PREVALENCE, BY GEOGRAPHY, (2009)
    • TABLE 93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY, (2009)
    • TABLE 94 ANEMIA PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 96 CROHN?S DISEASE PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 97 PSORIASIS PREVALENCE, BY GEOGRAPHY, 2009
    • TABLE 98 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 99 TOTAL REVENUES, BY GEOGRAPHY
    • TABLE 100 TOTAL REVENUES, 2006-2010
    • TABLE 101 SEGMENT SPECIFIC REVENUES ($MILLION)
    • TABLE 102 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
    • TABLE 103 TOTAL REVENUES, BY GEOGRAPHY
    • TABLE 104 REVENUES, BY SEGMENTS
    • TABLE 105 TOTAL REVENUES & NET INCOME ($MILLION)
    • TABLE 106 TOTAL REVENUES, 2007-2009
    • TABLE 107 BAXTER BIOPHARMA-TOTAL REVENUES & R&D EXPENSES ($MILLION)
    • TABLE 108 BAXTER BIOPHARMA-TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 109 BAXTER BIOPHARMA-TOTAL REVENUES, BY SEGMENTS ($MILLION)
    • TABLE 110 BAXTER BIOPHARMA-TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)
    • TABLE 111 BECTON DICKINSON-TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
    • TABLE 112 BECTON DICKINSON-TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 113 BECTON DICKINSON-TOTAL REVENUES, BY SEGMENTS ($MILLION)
    • TABLE 114 BECTON DICKINSON-TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)
    • TABLE 115 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 116 REVENUES, BY SEGMENTS ($MILLION)
    • TABLE 117 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
    • TABLE 118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)
    • TABLE 119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
    • TABLE 120 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 121 REVENUES, BY PRODUCTS
    • TABLE 122 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 123 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
    • TABLE 124 PRODUCT SALES, BY THERAPEUTIC AREA
    • TABLE 125 REVENUES & R&D EXPENDITURE
    • TABLE 126 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 127 REVENUES, BY BUSINESS SEGMENTS
    • TABLE 128 REVENUES, BY PRODUCTS
    • TABLE 129 REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 130 TOTAL REVENUES & EXPENDITURE
    • TABLE 131 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 132 NEKTAR-TOTAL REVENUES & R&D EXPENSES
    • TABLE 133 NEKTAR-TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 134 QLT-TOTAL REVENUES & R&D EXPENSES ($MILLION)
    • TABLE 135 QLT-TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 136 TOTAL REVENUES & R&D EXPENSES ($MILLION)
    • TABLE 137 SURMODICS INC.-TOTAL REVENUES & R&D EXPENSES ($MILLION)
    • TABLE 138 SURMODICS INC.-TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
    • TABLE 139 SURMODICS INC.-TOTAL REVENUES, BY SEGMENTS ($MILLION)
    • TABLE 140 TOTAL REVENUES & R&D EXPENDITURE
    • TABLE 141 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
    • TABLE 142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)
  • LIST OF FIGURES
    • FIGURE 1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
    • FIGURE 2 TOP 10 DRUG DELIVERY TECHNOLOGIES-MARKET SHARE
    • FIGURE 3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
    • FIGURE 4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
    • FIGURE 5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
    • FIGURE 6 DRUG DELIVERY MARKET STAKEHOLDERS
    • FIGURE 7 IMPACT OF MARKET DRIVERS & RESTRAINTS
    • FIGURE 8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
    • FIGURE 9 PATENT ANALYSIS, BY SEGMENTS, (2004-2009)
    • FIGURE 10 PATENT ANALYSIS, BY ASSIGNEE, (2004-2009)
    • FIGURE 11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
    • FIGURE 12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
    • FIGURE 13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
    • FIGURE 14 TARGETED THERAPY TYPES
    • FIGURE 15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
    • FIGURE 16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
    • FIGURE 17 EVOLUTION OF INHALER TECHNOLOGY
    • FIGURE 18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
    • FIGURE 19 COMPETITIVE DEVELOPMENTS, 2007-JUNE 2010
    • FIGURE 20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS, 2007-JUNE 2010
    • FIGURE 21 REVENUE ANALYSIS, 2008-2009
    • FIGURE 22 CONTROLLED RELEASE, DRUG FORMULATION-MARKET SHARE
    • FIGURE 23 R&D EXPENDITURE, 2008-2009
    • FIGURE 24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
    • FIGURE 25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
    • FIGURE 26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET-NORTH AMERICA
    • FIGURE 27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET-EUROPE
    • FIGURE 28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET-ASIA
    • FIGURE 29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET-ROW
+44 20 8816 8548

Ask a question about Top 10 Drug Delivery Technologies Market

Enter the characters you see in the picture below
Captcha